- PR Newswire•3 days agoVeracyte Announces Ten New Blues Plan Coverage Policies for Its Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2017 /PRNewswire/ -- Veracyte, Inc. (VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced that ten Blues plans have recently issued new positive coverage policies for the Afirma Gene Expression Classifier (GEC), deeming it a medically necessary benefit for their nearly 24 million collective members. The genomic test, which is used in thyroid cancer diagnosis, is now covered for nearly 225 million Americans, including more than 70 million Blues plan members. The coverage policies make the Afirma GEC available to Blues plan members in Alabama, Florida, Idaho, Kansas, Michigan, Missouri, Western New York, North Carolina, Tennessee and Wyoming.
- PR Newswire•9 days agoVeracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2016 Financial Results on Wednesday, March 1, 2017
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its fourth quarter and full-year 2016 financial results after close of market ...
- Zacks•15 days ago
Quest Diagnostics Incorporated (DGX) has recently entered into an agreement with genomic diagnostics company Veracyte, Inc. (VCYT), for the extended access of Afirma Gene Expression Classifier (GEC).
VCYT : Summary for Veracyte, Inc. - Yahoo Finance
Veracyte, Inc. (VCYT)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||7.84 x 100|
|Ask||8.01 x 300|
|Day's Range||7.73 - 8.15|
|52 Week Range||4.21 - 8.48|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-6.32|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|